CA2227370A1 - Procedes pour tuer selectivement des cellules ou inhiber selectivement la croissance de cellules exprimant le gene waf1 - Google Patents

Procedes pour tuer selectivement des cellules ou inhiber selectivement la croissance de cellules exprimant le gene waf1 Download PDF

Info

Publication number
CA2227370A1
CA2227370A1 CA 2227370 CA2227370A CA2227370A1 CA 2227370 A1 CA2227370 A1 CA 2227370A1 CA 2227370 CA2227370 CA 2227370 CA 2227370 A CA2227370 A CA 2227370A CA 2227370 A1 CA2227370 A1 CA 2227370A1
Authority
CA
Canada
Prior art keywords
cells
waf1
inhibitor
wafl
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2227370
Other languages
English (en)
Inventor
Alonzo H. Ross
Wojciech Poluha
Dorota K. Poluha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts UMass
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2227370A1 publication Critical patent/CA2227370A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des procédés pour tuer sélectivement des cellules ou inhiber la croissance de cellules. L'invention consiste à administrer un inhibiteur de WAF1 à des cellules ayant induit un processus dépendant de WAF1. La quantité d'inhibiteur WAF1 administrée aux cellules est suffisante pour inhiber leur croissance ou même tuer les cellules. Le procédé peut consister à soumettre les cellules à un traitement qui induira un processus dépendant de WAF1.
CA 2227370 1995-07-20 1996-07-19 Procedes pour tuer selectivement des cellules ou inhiber selectivement la croissance de cellules exprimant le gene waf1 Abandoned CA2227370A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US124895P 1995-07-20 1995-07-20
US60/001,248 1995-07-20

Publications (1)

Publication Number Publication Date
CA2227370A1 true CA2227370A1 (fr) 1997-02-06

Family

ID=21695094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2227370 Abandoned CA2227370A1 (fr) 1995-07-20 1996-07-19 Procedes pour tuer selectivement des cellules ou inhiber selectivement la croissance de cellules exprimant le gene waf1

Country Status (4)

Country Link
EP (1) EP0850066A1 (fr)
AU (1) AU6548396A (fr)
CA (1) CA2227370A1 (fr)
WO (1) WO1997003681A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
US6274576B1 (en) * 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
JP4205165B2 (ja) 1996-05-08 2009-01-07 サイクラセル リミテッド Ｃｄｋ４活性の阻害のための方法と手段
EP0941124A4 (fr) * 1996-11-21 2004-12-15 Univ Nebraska Compositions d'oligonucleotides antisens pour tuer selectivement les cellules cancereuses
MX2007002169A (es) 2004-08-27 2007-08-14 Cyclacel Ltd Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis

Also Published As

Publication number Publication date
WO1997003681A1 (fr) 1997-02-06
AU6548396A (en) 1997-02-18
EP0850066A1 (fr) 1998-07-01

Similar Documents

Publication Publication Date Title
KR100316205B1 (ko) 평활근세포의증식을조절하기위한c-myc의안티센스억제
US5990088A (en) Method for treating kaposi's sarcoma with antisense oligonucleotides
JP3231779B2 (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
US5734039A (en) Antisense oligonucleotides targeting cooperating oncogenes
TWI231312B (en) Novel dumbbell decoy oligodeoxynucleotides and use thereof
JP2011172597A (ja) スプライス領域アンチセンス組成物および方法
JPH09507381A (ja) 血管平滑筋細胞の増殖の阻害
EP0732929A1 (fr) Utilisation therapeutique de leurres d'elements cis in vivo
JP2003524637A (ja) Ｌｎａ修飾オリゴヌクレオチドの治療上の使用
KR20100081994A (ko) 섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절
Cucco et al. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides
JPH10508760A (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
US6579856B2 (en) Inhibition of stress activated protein kinase (SAPK) pathway and sensitization of cells to cancer therapies
WO1997011170A1 (fr) Chimiotherapie par oligonucleotides antisens de l'hypertrophie ou du cancer de la prostate
JP2003525037A (ja) Ｃｄ２０およびｎｏｇｏ遺伝子発現の調節および診断のための方法および試薬
JPH06509333A (ja) ニューロトロフィン活性に対する方法およびアッセイ系
JP2003500418A (ja) 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス
KR20010042848A (ko) 인슐린유사 성장인자 ⅱ의 안티센스 올리고뉴클레오타이드서열 및 이를 이용한 세포성장 조절방법
JPH10512559A (ja) 過増殖症の併用療法
CA2227370A1 (fr) Procedes pour tuer selectivement des cellules ou inhiber selectivement la croissance de cellules exprimant le gene waf1
US5935937A (en) Compositions and methods for inducing apoptosis
JP2003512442A (ja) 癌の治療法
WO2019240164A1 (fr) Agent thérapeutique contre le dysfonctionnement myocardique
WO1998049287A2 (fr) Oligonucleotides antisens specifiques d'une thymidylate synthase
EP1485117A2 (fr) Methodes de traitement therapeutique de l'hypertrophie benigne de la prostate (bph)

Legal Events

Date Code Title Description
FZDE Dead